March 31, 2020
Vitamin D Therapy

Vitamin D Therapy Market growth drivers, opportunities and forecast analysis to 2027

The global market for vitamin D therapy was valued at US$ 1,919.4 million in 2018 and is expected to hit US$ 4,721.9 million by 2027, increasing to CAGR by 10.6 per cent from 2019 to 2027.

Market Insights :

Osteoporosis is a disease manifested by low bone density, deterioration of bone tissue, and decreased bone strength, which increases the risk of fracture. It is one of the most common causes of mortality in elderly patients and young children suffering from malnutrition. Risk factors associated with vitamin D deficiency include ageing, low dietary intake of calcium, genetic predisposition, decreased physical activity, and abnormal thyroid function.

Access Free Sample Copy of Research Report:

[Note: Our Free Complimentary Sample Report Accommodate a Brief Introduction To The Synopsis, TOC, List of Tables and Figures, Competitive Landscape and Geographic Segmentation, Innovation and Future Developments Based on Research Methodology are also Included]

Oral route of administration dominates the market for vitamin D therapy. It has garnered immense popularity among children due to ease of administration and has been formulated in different sizes and colours to increase its external appearance and to increase the palatability of sugar coating. The parenteral route of administration is superior due to its excellent pharmacokinetic and pharmacodynamic drug profile and useful in the elderly population with impaired absorption of vitamin D via the gastrointestinal tract.

Osteoporosis is currently the application segment of the market for vitamin D therapy. According to the International Osteoporosis Foundation (IOF) research studies, 1 in 3 women and 1 in 5 men over 50 years of age will have an osteoporotic fracture at least once in their lifetime. Malnutrition and depletion of calcium and vitamin D I daily dietary intake has led to a significant increase in rickets in young children in developing and poor countries. Over the last 2 decades, skin disease has been on the rise due to the depletion of ozone layers, which has exposed the skin to harmful UV radiation, depleting the keratinocytes used in vitamin D synthesis, causing inflammatory skin diseases such as atopic dermatitis and psoriasis.

For Any Query, Ask Our Expert at:

North America currently holds a 33% market share in the regional vitamin D market. The main factors contributing to North America’s dominance are increasing osteoporosis prevalence and low bone mass, and increasing public health awareness of vitamin D deficiency. Europe is the second-largest market with a 30 per cent share due to the increasing prevalence of skin disorders associated with low serum cholecalciferol levels. The Asia Pacific holds 20% market share and is willing to enter the market in the near future due to a significant increase in malnourishment in young children resulting in rickets and the home of key players such as Cadila Healthcare, Alkem Laboratories, Torrent Pharmaceuticals Ltd., etc., driving market growth in the region.

  • Pharmaceutical companies providing vitamin D therapy are Abbott Laboratories, Inc., Alkem Laboratories, Cadila Healthcare Ltd., GlaxoSmithKline, Plc., Merck & Co., Inc., Novartis AG, Pfizer, Inc., Sanofi S.A., Sun Pharmaceutical Industries Ltd. and Torrent Pharmaceutical Ltd.
  • Significant increase in malnutrition among young children in developing and poor nations resulting in rickets.
  • Favourable refund scenario for vitamin D therapy products.

Key questions answered in this report

  • What is the competitive scenario existing in the vitamin D therapy market?
  • What are the latest collaboration and strategic mergers and acquisitions taking place in the vitamin D therapy market?
  • What is the disease etiology and prevalence rate associated with bone and skin deformities due to vitamin D deficiency?
  • Which risk factors are associated with the occurrence of osteoporosis and rickets?
  • What are the different formulation aspects associated with oral and parenteral route of administration?
  • What will be the market performance in both developed and developing nations?

Access Free Sample Copy of Research Report:

Leave a Reply

Your email address will not be published. Required fields are marked *